Biblio Discovery — Demo Discovery Service

12 hasil untuk "Lin, Swan"

Menampilkan 1–12 · 0,63 detik · RSS

  1. Artikel Jurnal Teks lengkap

    Effects of H2-Receptor Antagonists on the Exposure of Dacomitinib

    Liu, Jian; Lin, Swan; Huynh, Anthony dkk.

    Pharmaceutics · 2024 · Inggris · PubMed Central

    Dacomitinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor indicated for the treatment of patients with advanced non-small-cell lung cancer (NSCLC) and EGFR-activating mutations. Proton-pump inhibitors decreased dacomitinib exposure. This analysis summarizes…

  2. Artikel Jurnal Teks lengkap

    An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure

    Lin, Swan; Shaik, Naveed; Chan, Geoffrey dkk.

    Cancer Chemother Pharmacol · 2020 · Inggris · PubMed Central

    PURPOSE: Glasdegib, an oral inhibitor of the Hedgehog signaling pathway, is approved in the United States in combination with low-dose cytarabine (LDAC) to treat patients with newly diagnosed acute myeloid leukemia (AML) ineligible to receive intensive chemotherapy. This population…

  3. Artikel Jurnal Teks lengkap

    Evaluation of the Relationship of Glasdegib Exposure and Safety End Points in Patients With Refractory Solid Tumors and Hematologic Malignancies

    Ruiz‐Garcia, Ana; Shaik, Naveed; Lin, Swan dkk.

    J Clin Pharmacol · 2020 · Inggris · PubMed Central

    Glasdegib is approved for treating acute myeloid leukemia in elderly patients at 100 mg once daily in combination with low‐dose cytarabine. Exposure‐efficacy analysis showed that the survival benefit of glasdegib was not glasdegib exposure‐dependent. The relationship between glasdegib exposure and…

  4. Artikel Jurnal Teks lengkap

    Population Pharmacokinetics of Glasdegib in Patients With Advanced Hematologic Malignancies and Solid Tumors

    Lin, Swan; Shaik, Naveed; Martinelli, Giovanni dkk.

    J Clin Pharmacol · 2019 · Inggris · PubMed Central

    Glasdegib is an inhibitor of the Hedgehog pathway recently approved in the United States for the treatment of acute myeloid leukemia. A population pharmacokinetic analysis was conducted to characterize the kinetic behavior of glasdegib and its sources of variability (covariates) by utilizing data…

  5. Artikel Jurnal Teks lengkap

    Application of Machine Learning for Predicting Progression‐Free and Overall Survival in Patients With Renal Cell Carcinoma

    Grant, Caroline W.; Li, Jerry; Lin, Swan dkk.

    Clin Transl Sci · 2025 · Inggris · PubMed Central

    Patient outcomes in advanced renal cell carcinoma (RCC) remain poor, with five‐year survival rates ranging from ~10% to 30%. Early projections of therapeutic outcomes could optimize precision medicine and accelerate drug development. While machine learning (ML) models integrating tumor growth…

  6. Artikel Jurnal Teks lengkap

    Pharmacokinetic Models to Characterize the Absorption Phase and the Influence of a Proton Pump Inhibitor on the Overall Exposure of Dacomitinib

    Ruiz-Garcia, Ana; Tan, Weiwei; Li, Jerry dkk.

    Pharmaceutics · 2020 · Inggris · PubMed Central

    Introduction: Dacomitinib is an epidermal growth factor receptor (EGFR) inhibitor approved for the treatment of metastatic non-small cell lung cancer (NSCLC) in the first line in patients with EGFR activating mutations. Dacomitinib is taken orally once daily at 45 mg with or without food, until…

  7. Artikel Jurnal Teks lengkap

    Effects of the selective AMPA modulator NBI‐1065845 on the pharmacokinetics of midazolam or ethinyl estradiol–levonorgestrel in healthy adults

    Lin, Swan; Ionescu, Adrian; Maynard‐Scott, Jessica dkk.

    Clin Transl Sci · 2024 · Inggris · PubMed Central

    This parallel‐arm, phase I study investigated the potential cytochrome P450 (CYP)3A induction effect of NBI‐1065845 (TAK‐653), an investigational α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid receptor potentiator in phase II development for major depressive disorder. The midazolam treatment…

  8. Artikel Jurnal Teks lengkap

    A Phase I Study to Evaluate the Pharmacokinetics and Safety of Lorlatinib in Adults with Mild, Moderate, and Severe Renal Impairment

    Lin, Swan; Gong, Jason; Canas, George C. dkk.

    Eur J Drug Metab Pharmacokinet · 2022 · Inggris · PubMed Central

    BACKGROUND AND OBJECTIVES: Lorlatinib is approved (100 mg once daily [QD]) for the treatment of patients with anaplastic lymphoma kinase- (ALK) positive metastatic non-small cell lung cancer. This study evaluated the impact of varying degrees of renal impairment on the safety and pharmacokinetics…

  9. Artikel Jurnal Teks lengkap

    A Role for Low Density Lipoprotein Receptor-related Protein 1 in the Cellular Uptake of Tissue Plasminogen Activator in the Lungs

    Lin, Swan; Racz, Jennifer; Tai, Melissa F. dkk.

    Pharm Res · 2015 · Inggris · PubMed Central

    PURPOSE: To gain knowledge of lung clearance mechanisms of inhaled tissue plasminogen activator (tPA). METHODS: Using an in vivo mouse model and ex vivo murine whole organ cell suspensions, we examined the capability of the lungs to utilize LRP1 receptor-mediated endocytosis (RME) for the uptake of…

  10. Artikel Jurnal Teks lengkap

    Evaluation of Omeprazole Limited Sampling Strategies to Estimate Constitutive Cytochrome P450 2C19 Activity in Healthy Adults

    Lin, Swan; Nikanjam, Mina; Capparelli, Edmund V. dkk.

    Ther Drug Monit · 2018 · Inggris · PubMed Central

    PURPOSE: Limited sampling strategy (LSS) is a validated method to estimate pharmacokinetic (PK) parameters from a reduced number of samples. Omeprazole is used to phenotype in vivo cytochrome P450 (CYP) 2C19 activity. This study examined a LSS using two estimation methods to determine apparent oral…

  11. Artikel Jurnal Teks lengkap

    A Phase 2 Randomized Trial of NBI-1065846 (TAK-041) in Patients With Anhedonia Associated With Major Depressive Disorder

    Benedetto, Shannon R.; Ionescu, Adrian; Ge, Tingting dkk.

    J Clin Psychopharmacol · 2025 · Inggris · PubMed Central

    BACKGROUND: Anhedonia is a core symptom of major depressive disorder (MDD) that may result from aberrant lateral habenula hyperactivity. Targeting G-protein coupled receptor 139 (GPR139) may improve anhedonia by modulating lateral habenula activity. NBI-1065846 is an investigational GPR139 agonist…